BISPECTRA

100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	6-Sep-2019	ר ר	6-Sep-2022	: Date of Next Review
Prepared By:	Kyle Snyder	7 [16-002354 v.1.0	: Supersedes
QA/QC Approval:	Danielle Gathagan	7 [Dora Meissner	: Management Approval
Reason for Revision:	See Revision History in ensur			

CERTIFICATE OF ANALYSIS POTASSIUM BROMIDE BIO ACTIVE GRADE / PB2220 – G500 LOT#: PB2220-005-1019

KBr & F.W. 119.00g/mol. & CAS#: 7758-02-3 Manufacturing Date: 7/28/2019 Retest Date: 7/31/2021 Manufacturing Site: 100 Majestic Way, Bangor PA, 18013 Packaging Date: 10/24/2019 Packaging Site: 100 Majestic Way, Bangor PA, 18013

Meets or exceeds USP Specifications

Test		Specification	TEST RESULT
Acidity or Alkalinity		Passes Test	Passes Test
Appearance of Solution		Clear and Colorless	Clear and Colorless
Assay		98.0 - 100.5%	99.60%
Bromates		Passes Test	Passes Test
Heavy Metals		10 ppm max.	< 10. ppm
Identity	А	Passes Test	Passes Test
Identity	В	Passes Test	Passes Test
Iodides		Passes Test	Passes Test
Limit of Chlorine		0.6% max.	<0.01%
Limit of Iron		20 ppm max.	< 20 ppm
Loss on Drying		1.0% max.	0.0925%
Magnesium and Alkaline Earth-Metals		0.02% max.	<0.02%
Sulfates		0.01% max.	<0.01%
	Arsenic (As)	5 ppm max.	< 5 ppm
Trace Metals	Copper (Cu)	5 ppm max.	< 5 ppm
Trave Michais	Iron (Fe)	5 ppm max.	< 5 ppm
	Lead (Pb)	5 ppm max.	< 5 ppm

COUNTRY OF ORIGIN: U.S.A.

TEST METHOD REFERENCE: DCN: 16-001310

CAUTION STATEMENT: For use in development only and not for commercial distribution.

INTENDED USE: Material represented by this Certificate of Analysis is suitable to be used only as the following: ICH Q7 Compliant cGMP Manufactured Active Pharmaceutical Ingredient for use in Drug Product Manufacturing. The material represented by this Certificate of Analysis is not suitable to be used as a Sterile or Injectable Active Pharmaceutical Ingredient, Drug Product or Household Item.

RESIDUAL SOLVENTS STATEMENT: Based on the manufacturing process and the controlled handling and storage of this product, there is no potential for any of the residual solvents listed in the current USP method <467> Tables 1, 2, 3, or 4 to be present at the specified limits; furthermore, if tested this product would comply with USP/NF requirements.

Prepared By:	C_{i}	Date: 1/15/19

Reviewed By: <u>H.B.enn</u> Date: <u>H15/19</u>